(Total Views: 238)
Posted On: 09/15/2021 7:13:35 AM
Post# of 6
Lets see this in the News Headlines on 03/29/22....FDA Approved the drug
Generic name: vadadustat developed by Akebia Therapeutics, Inc. for
treatment of Anemia Associated with Chronic Renal Failure
Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor in development for the treatment of anemia due to chronic kidney disease (CKD) in adults. If we get FDA Approval share price will fly to the $12 - $15 range if we also gets approval for non dialysis patients we can see share price fly past $15 onwards up to $30 share price!
Generic name: vadadustat developed by Akebia Therapeutics, Inc. for
treatment of Anemia Associated with Chronic Renal Failure
Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor in development for the treatment of anemia due to chronic kidney disease (CKD) in adults. If we get FDA Approval share price will fly to the $12 - $15 range if we also gets approval for non dialysis patients we can see share price fly past $15 onwards up to $30 share price!
(0)
(0)
